Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Jebel Ali Port welcomes historic first call of new Gemini service 10 Incredible features of the Avro Vulcan bomber Emirates launches new and elevated Business Class in-flight menu Footprints from ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... These statistics make oncology one of ...

Fred Alger Management, an investment management company, released its “Alger Spectra Fund” fourth quarter 2024 investor ...

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as effective as bariatric surgery.

Jonsson says scientists inside the company are already working on making a yearly weight-loss shot a reality. Here are the small steps they're taking this year to get there. Eli Lilly's oral ...

Eli Lilly presents positive results from VIVID-2 open-label extension study of Omvoh to treat Crohn's disease at Crohn's and Colitis Congress: Indianapolis Monday, February 10, 20 ...

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Focus Growth Strategy” fourth quarter 2024 investor ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...